These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30098518)

  • 21. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.
    Pal R; Janz M; Galson DL; Gries M; Li S; Jöhrens K; Anagnostopoulos I; Dörken B; Mapara MY; Borghesi L; Kardava L; Roodman GD; Milcarek C; Lentzsch S
    Blood; 2009 Oct; 114(18):3890-8. PubMed ID: 19717648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
    Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
    Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcription factor IRF4 regulates germinal center cell formation through a B cell-intrinsic mechanism.
    Willis SN; Good-Jacobson KL; Curtis J; Light A; Tellier J; Shi W; Smyth GK; Tarlinton DM; Belz GT; Corcoran LM; Kallies A; Nutt SL
    J Immunol; 2014 Apr; 192(7):3200-6. PubMed ID: 24591370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.
    Perini T; Materozzi M; Milan E
    FEBS J; 2022 Aug; 289(15):4383-4397. PubMed ID: 34117720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.
    Agnelli L; Storti P; Todoerti K; Sammarelli G; Dalla Palma B; Bolzoni M; Rocci A; Piazza F; Semenzato G; Palumbo A; Neri A; Giuliani N
    Am J Hematol; 2011 Dec; 86(12):E64-6. PubMed ID: 21953534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MUM1/IRF4: A Review.
    Gualco G; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):301-10. PubMed ID: 20182347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon regulatory factor 4 and 8 in B-cell development.
    Lu R
    Trends Immunol; 2008 Oct; 29(10):487-92. PubMed ID: 18775669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma.
    Huo J; Xu S; Lin B; Chng WJ; Lam KP
    Leukemia; 2013 Apr; 27(5):1165-71. PubMed ID: 23138182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zinc finger-IRF composite elements bound by Ikaros/IRF4 complexes function as gene repression in plasma cell.
    Ochiai K; Kondo H; Okamura Y; Shima H; Kurokochi Y; Kimura K; Funayama R; Nagashima T; Nakayama K; Yui K; Kinoshita K; Igarashi K
    Blood Adv; 2018 Apr; 2(8):883-894. PubMed ID: 29669755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development.
    Nam S; Lim JS
    Arch Pharm Res; 2016 Nov; 39(11):1548-1555. PubMed ID: 27826752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
    Jourdan M; De Vos J; Mechti N; Klein B
    Cell Death Differ; 2000 Dec; 7(12):1244-52. PubMed ID: 11175262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency.
    Thouenon R; Chentout L; Moreno-Corona N; Poggi L; Lombardi EP; Hoareau B; Schmitt Y; Lagresle-Peyrou C; Bustamante J; André I; Cavazzana M; Durandy A; Casanova JL; Galicier L; Fadlallah J; Fischer A; Kracker S
    J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36917008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.
    Klein U; Casola S; Cattoretti G; Shen Q; Lia M; Mo T; Ludwig T; Rajewsky K; Dalla-Favera R
    Nat Immunol; 2006 Jul; 7(7):773-82. PubMed ID: 16767092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.
    Teng Y; Takahashi Y; Yamada M; Kurosu T; Koyama T; Miura O; Miki T
    Eur J Cell Biol; 2007 Oct; 86(10):581-9. PubMed ID: 17651861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.
    Vora AA; Mondala PK; Costello C; MacLeod AR; Crews LA
    STAR Protoc; 2021 Jun; 2(2):100565. PubMed ID: 34136833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diverse roles of IRF4 in late germinal center B-cell differentiation.
    De Silva NS; Simonetti G; Heise N; Klein U
    Immunol Rev; 2012 May; 247(1):73-92. PubMed ID: 22500833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
    Li N; Johnson DC; Weinhold N; Studd JB; Orlando G; Mirabella F; Mitchell JS; Meissner T; Kaiser M; Goldschmidt H; Hemminki K; Morgan GJ; Houlston RS
    Nat Commun; 2016 Nov; 7():13656. PubMed ID: 27882933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.
    Mondala PK; Vora AA; Zhou T; Lazzari E; Ladel L; Luo X; Kim Y; Costello C; MacLeod AR; Jamieson CHM; Crews LA
    Cell Stem Cell; 2021 Apr; 28(4):623-636.e9. PubMed ID: 33476575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.